ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Granulomatosis with Polyangiitis (GPA)"

  • Abstract Number: 0416 • ACR Convergence 2021

    Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis

    Jason Springer1 and Ryan Funk2, 1Vanderbilt University Medical Center, Franklin, TN, 2University of Kansas Medical Center, Kansas City, KS

    Background/Purpose: Rituximab (RTX) has demonstrated efficacy in maintenance therapy in ANCA-associated vasculitis. However, different dosing protocols have been used in clinical trials and there is…
  • Abstract Number: 0421 • ACR Convergence 2021

    Negative vs. Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis, a Case-control Study

    Marta Casal Moura, Samuel D. Falde, Ulrich Specks and Misbah Baqir, Mayo Clinic, Rochester, MN

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) negative granulomatosis with polyangiitis (GPA) is a challenging diagnosis. There is paucity of literature regarding the clinical course of ANCA-negative…
  • Abstract Number: 0431 • ACR Convergence 2021

    Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study

    Eduardo Martin-Nares, Lilian Guadalupe Cano Cruz and Andrea Hinojosa-Azaola, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: Hypertrophic pachymeningitis (HP) is an infrequent manifestation in autoimmune and non-autoimmune conditions. The differences in clinical characteristics and outcomes of ANCA-associated and non-immune-mediated HP…
  • Abstract Number: 0436 • ACR Convergence 2021

    Ocular and Orbital Manifestations of Granulomatosis with Polyangiitis: A Systematic Review of Published Cases

    Madeleine Yeakle1, Allen Tsiyer1, Daniel Bishev1, Kayvon Moin1, Victoria Garofalo1, Allison Parrill1, Alexander Hatsis2, Tyler Wickas2 and Prachi Anand3, 1American University of the Caribbean School of Medicine, Cupecoy, Netherlands Antilles, 2Department of Ophthalmology, Nassau University Medical Center, East Meadow, NY, 3Department of Rheumatology, Nassau University Medical Center, East Meadow, NY

    Background/Purpose: Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s Granulomatosis, is a systemic autoimmune condition caused by granulomatous inflammation of small and medium arteries, arterioles…
  • Abstract Number: 0525 • ACR Convergence 2021

    STEAP3, FZD2 and EGFLAM Are Novel Genetic Risk Loci for Granulomatosis with Polyangitis: A Genome Wide Association Study from UK Biobank

    Mehmet Hocaoglu1, Jamal Mikdashi2, Yi-Ju Chen2, James Perry2 and Charles Hong2, 1University of Maryland Medical Center, Midtown Campus, Baltimore, MD, 2University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Granulomatosis with Polyangitis (GPA) is a systemic ANCA associated small vessel vasculitis. Prior genetic studies demonstrated a strong association of HLA Class II region…
  • Abstract Number: 1420 • ACR Convergence 2020

    Characterization of ANCA-Associated Vasculitis Among African American Patients

    Sehris Khawaja1, Saloni Godbole1, Maryann Kimoto2, Virginia Steen3 and Kaitlin Quinn4, 1Georgetown University, Washington, DC, 2UCLA, Los Angeles, CA, 3Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, 4National Institutes of Health, Washington, DC

    Background/Purpose: ANCA-associated vasculitis (AAV) comprises a group of disorders characterized by inflammation of small and medium-sized arteries.  Prevalence and phenotype of these diseases appear to…
  • Abstract Number: 1421 • ACR Convergence 2020

    Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans

    Luis Palomino1, Angelo Gaffo2, Sebastian Sattui3 and Dongmei Sun2, 1University of Alabama at Birmingham Hospital, Birmingham, AL 2University of Alabama at Birmingham, Birmingham, AL, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: ANCA-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA), affect mostly Caucasians of European descent. Clinical…
  • Abstract Number: 1425 • ACR Convergence 2020

    Reduced Risk of Cardiovascular Diseases Events with Renal Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System

    Zachary Wallace1, April Jorge2, Xiaoqing Fu3, Yuqing Zhang4 and Hyon Choi5, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Boston, 4Massachusetts General Hospital, Quincy, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: Granulomatosis with polyangiitis (GPA) is a common cause of glomerulonephritis and leads to end-stage renal disease (ESRD) in approximately 25% of patients. Both GPA…
  • Abstract Number: 1430 • ACR Convergence 2020

    The Role of Lung Biopsy in Pediatric ANCA-associated Vasculitis

    Edouard Sayad1, Tiphanie Vogel1, David Moreno McNeill1, Nahir Cortes-Santiago1, David Spielberg1, Kalyani Patel1 and Manuel Silva Carmona1, 1Baylor College of Medicine/Texas Children's Hospital, Houston, TX

    Background/Purpose: Anca-associated vasculitis (AAV) is characterized by vascular inflammation in multiple organs. The diagnosis can be made clinically using a number of different criteria. The…
  • Abstract Number: 1438 • ACR Convergence 2020

    Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)

    Jason Springer1 and Ryan Funk2, 1University of Kansas Medical Center, Overland Park, KS, 2UNIVERSITY OF KANSAS, Kansas City, KS

    Background/Purpose: Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, has been shown to be an effective maintenance therapy for granulomatosis with polyangitiis (GPA) and microscopic polyangiitis…
  • Abstract Number: 1524 • ACR Convergence 2020

    Interstitial Lung Disease, Kidney Inflammation and Myositis Are Induced by Transfer of PBMC Derived from Systemic Sclerosis Patients into Rag2-/-/ IL2rg-/- mice

    Xiaoyang Yue1, Frank Petersen1, Xinhua Yu1, Gabriela Riemekasten2, Peter Lamprecht3, Antje Müller3 and Junping Yin4, 1Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL), Borstel, Germany, 2University of Lübeck, Department of Rheumatology and Clinical Immunology,, Lübeck, Germany, 3University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 41 Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL),, Borstel, Germany

    Background/Purpose: To explore the pathogenic potential of lymphocytes in systemic sclerosis (SSc) and granulomatosis with polyangiitis (GPA), a humanized mouse model was generated by transferring…
  • Abstract Number: 2048 • ACR Convergence 2020

    Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis

    Valerie Benard1, Cynthia Farhat2, Melissa Zarandi-Nowroozi2, Madeleine Durand3, Christian Pagnoux4, Pierre Charles5, Xavier Puechal6, Loïc Guillevin7 and Jean-Paul Makhzoum1, 1Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Internal Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada, 2Department of Medecine, University of Montreal, Montreal, QC, Canada, 3Department of Internal Medicine, Centre Hospitalier de l’Universite de Montreal (CHUM) and Centre de Recherche du Centre Hospitalier de l’Universite de Montreal (CRCHUM), Montreal, QC, Canada, 4Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, 7Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France

    Background/Purpose: Organ or life-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two of the antineutrophil cytoplasm antibody-associated vasculitis (AAV), are treated with cyclophosphamide or…
  • Abstract Number: 2049 • ACR Convergence 2020

    Nasal Bacteria Associated with Disease Activity and ANCA Levels in Granulomatosis with Polyangiitis

    Rennie Rhee1, Jiarui Lu1, Kyle Bittinger2, Antoine Sreih1, Jung-Jin Lee3, Lisa Mattei3, Brendan Kelly4, Peter C. Grayson5, Hongzhe Lee4, Ronald Collman4 and Peter Merkel1, 1University of Pennsylvania, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Children's Hospital of Philadelphia, Philadelphia, 4University of Pennsylvania, Philadelphia, 5Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

    Background/Purpose: Nasal bacteria have been linked to disease activity in granulomatosis with polyangiitis (GPA) with most studies focused on Staphylococcus aureus. Our previous study identified…
  • Abstract Number: 2050 • ACR Convergence 2020

    Autoantibodies Targeting Complement Receptors C3aR and C5aR1 Are Decreased in ANCA-associated Vasculitis and Correlate with a Higher Relapse Rate

    Sebastian Klapa1, Antje Müller2, Andreas Koch3, Anja Kerstein-Staehle4, Wataru Kaehler3, Harald Heidecke5, Susanne Schinke6, Markus Huber-Lang7, Martin Nitschke8, Silke Pitann9, Christian Karsten10, Gabriela Riemekasten11 and Peter Lamprecht2, 1University of Lübeck and Institute of Experimental Medicine, Christian-Albrechts-University of Kiel c/o German Naval Medical Institute, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, 2University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 3Institute of Experimental Immunology, Christian-Albrechts-University Kiel, c/o German Naval Medical Institute, Kronshagen, Germany, 4University of Lübeck, Dept Rheumatology and Clinical Immunology, Luebeck, Germany, 5CellTrend GmbH, Luckenwalde, Germany, 6University of Lübeck, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, 7Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, Ulm, Germany, 8Department of Internal Medicine I, Transplant Center, University of Lübeck, Luebeck, Germany, 9University of Lübeck, Department of Rheumatology and Clinical Immunology,, Luebeck, Germany, 10Institute of Systemic Inflammation Research, University of Lübeck, Luebeck, Germany, 11University of Lübeck, Department of Rheumatology and Clinical Immunology,, Lübeck, Germany

    Background/Purpose: Activation of the alternative and common terminal complement pathways has been shown in ANCA-associated vasculitis (AAV). Circulating titers of the anaphylatoxin C5a are increased…
  • Abstract Number: 2051 • ACR Convergence 2020

    Localized versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Database

    Michele Iudici1, Christian Pagnoux2, Delphine Courvoisier3, Pascal Cohen4, Mohamed Hamidou5, Achille Aouba6, François Lifermann7, Marc Ruivard8, Olivier Aumaitre9, Bernard Bonnotte10, Julien Campagne11, Olivier Decaux12, Eric Hachulla13, Alexandre Karras14, Chahéra Khouatra15, Noémie Jourde-Chiche16, Jean-François Viallard17, Pascal Godmer18, Claire Blanchard-Delaunay19, Alain Le Quellec20, Thomas Quéméneur21, Claire de Moreuil22, Alexis Regent4, Benjamin Terrier4, Luc Mouthon4, Loïc Guillevin4 and Xavier Puechal4, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University and Geneva University Hospitals, Geneva, Switzerland, 2Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Division of rheumatology, Geneva University Hospitals, Geneva, Switzerland, 4National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, 5Department of Internal Medicine, Hôtel-Dieu, CHU Nantes, Nantes, France, 6Department of Internal Medicine, CHU Côte de Nacre, Caen, France, 7Department of Internal Medicine, CH Côte d’Argent, Dax, France, 8Department of Internal Medicine, CHU Estaing, Clermont Ferrand, France, 9Department of Internal Medicine, CHU Gabriel Montpied, Clermont Ferrand, France, 10CHU Dijon, Dijon, France, 11Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, 12CHU Rennes, Rennes, France, 13Department of Internal Medicine, CHRU, Lille Cedex, France, 14Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France, 15Department of Respiratory Medicine, CHU Louis Pradel, Lyon, France, 16Department of Nephrology, CHU de la Conception, Marseille, France, 17Department of Internal Medicine, CHU Haut-Lévêque, Bordeaux, France, 18Department of Internal Medicine, CH Bretagne Atlantique, Vannes, France, 19Department of Internal Medicine, CH, Niort, France, 20Department of Internal Medicine, CHU Saint Eloi, Montpellier, France, 21Department of Internal Medicine, CH, Valenciennes, France, 22Department of Internal Medicine, CHU Cavale Blanche, Brest, France

    Background/Purpose: The clinical picture at onset and evolution of localized forms of granulomatosis with polyangiitis (L-GPA) have already been investigated but, to our knowledge, have…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology